Mazdutide is a weight loss (glp-1/glucagon) peptide. Typical research dosing is once weekly injection, and the body of supporting research is phase 3 clinical trials.
Mazdutide (IBI362) is a dual GLP-1 receptor and glucagon receptor agonist developed by Innovent Biologics in China. It shares the dual-agonist approach of retatrutide but without the GIP component, instead pairing GLP-1 with glucagon agonism, which drives thermogenesis and direct fat oxidation. Browse all weight loss peptide options to compare.
In Phase 3 clinical trials conducted primarily in Chinese and Asian populations, Mazdutide demonstrated approximately 18% body weight reduction over 36 weeks, positioning it between tirzepatide (22.5%) and semaglutide (15%) in terms of efficacy. Given that clinical trial populations were Asian, results may be particularly relevant to Philippines users.
Mazdutide also shows promise beyond weight loss: trials have demonstrated improvements in NAFLD (fatty liver disease), with significant reductions in liver fat content. This makes it particularly interesting for users with metabolic liver conditions.
GLP-1 Agonism: Activates GLP-1 receptors to suppress appetite, enhance insulin secretion, and slow gastric emptying, the same core mechanism as Semaglutide and the GLP-1 component of Tirzepatide.
Glucagon Agonism: Activates glucagon receptors which directly increase metabolic rate (thermogenesis), stimulate fat oxidation particularly in the liver, and enhance energy expenditure. This is the key differentiator from pure GLP-1 drugs.
Hepatic Fat Reduction: The glucagon component has particular efficacy in reducing liver fat (hepatic triglycerides), making Mazdutide uniquely effective for NAFLD/MAFLD alongside its weight loss properties.
| Phase | Dose | Frequency | Duration |
|---|---|---|---|
| Starting | 3mg | Once weekly | Weeks 1–4 |
| Titration | 4.5–6mg | Once weekly | Weeks 5–12 |
| Maintenance | 6mg | Once weekly | Ongoing |
Always start at the lowest effective dose and titrate up gradually.
Turning a dose in milligrams into units on a syringe is arithmetic, not judgement. The reconstitution calculator does it for any vial size, and the rest of the calculator set covers cost per milligram and route comparison.
Vials at Primara Labs, our partner and supplier, ship from stock already inside the Philippines, so an order has no customs leg. Their catalogue is the shortest route to what is listed locally and at what price, and anything outside it goes through the same WhatsApp thread. View the Primara Labs catalogue
Starting dose phase. Appetite reduction begins. Nausea may occur but is typically manageable.
Appetite markedly reduced at titration dose. Weight loss accelerates, often 1–1.5kg per week with dietary awareness.
Consistent fat loss continues. The glucagon component produces noticeable thermogenic benefit. Users often report feeling warmer and more energetic.
Our partner and supplier
Primara Labs, our partner and supplier, ships from inventory already inside the Philippines, so there is no customs leg: vials are batch-numbered, Metro Manila orders dispatch same day, the rest of the country lands in one to three business days, and every order gets 10% off. The current list sits on one page, and anything you cannot see on it goes through the same WhatsApp thread.
View the Primara Labs catalogueThe supply index covers what to ask a seller before paying, and why quoted prices vary so widely.
Risk · Disclosure · Editorial Status
This page is editorial information for adults researching peptide therapy. It is not medical advice, not a prescription, and not an endorsement of any specific product, supplier, or protocol. Side effects can be serious and individual response varies. Talk to a licensed physician (ideally one with peptide-specific clinical experience) before starting any compound, adjusting a dose, or discontinuing therapy.
In the Philippines, GLP-1 medications are prescription-only under FDA Philippines regulation. Research-grade peptides occupy a regulatory gray area: import for personal research use is generally tolerated, but the Bureau of Customs reserves the right to inspect and detain shipments. Do not import for resale.
Editorial Status
Independent · Non-clinical
Affiliation
Not a clinic · Not a pharmacy
Last Updated
August 27, 2026
